Botanical Solution, a Santiago, Chile-based provider of a proprietary R&D platform for production of advanced botanical materials (ABM), raised additional $7.6M in funding.
The round, which brought the total amount of Series A to $23M, saw participation from undisclosed investors.
The company intends to use the funds to accelerate scalable commercial production of pharmaceutical grade QS-21 for human vaccines, R&D lab expansion, opening new markets for vaccine developers.
Led by CEO Gaston Salina, BSI provides a proprietary R&D platform for sustainable and improved production of high-quality advanced botanical materials (ABM). ABM-01 is the first ABM produced by the company, based on a tissue cultured plant calledĀ Quillaja saponaria. ABM-01 is the active ingredient used in two gold standard products, its biopesticide QuillibriumĀ® and the adjuvant QS-21, used in modern vaccine development.
QS-21 is a vital component in FDA-approved vaccines against Shingles and Respiratory Syncytial Virus (RSV).
BSI has already announced one key partnership for the QS-21 pharmaceutical adjuvant with Croda Pharma, and the larger production will open further opportunities for vaccine developers.
FinSMEs
26/08/2024